The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer

Özlem SÖNMEZ, (Acıbadem Mehmet Ali Aydınlar Üniversitesi, Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)
Elif ŞENOCAK TAŞÇI (Acıbadem Mehmet Ali Aydınlar Üniversitesi, Tıbbi Onkoloji Anabilim Dalı, İstanbul, Türkiye)
ACTA ONCOLOGICA TURCICA
1 0
Yıl: 2021 Cilt: 54 Sayı: 2 Sayfa Aralığı: 256 - 263 Metin Dili: İngilizce DOI: 10.5505/aot.2021.46693 İndeks Tarihi: 20-12-2021

The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer

Öz:
Breast cancer is a heterogenous disease with various morphological, clinical and molecular features. Traditionally, pathologic parameters and clinical stage of the disease are used to determine indication of adjuvant treatment, however these features are not sufficient to identify the patients that need treatment. Prognostic and predictive biomarkers are needed to develop personalized treatments. Predictive factors are indicators of response to a particular treatment. MammaPrint® (Agendia, Amsterdam, the Netherlands), Oncotype DX® (Genomic Health, Redwood City, CA), Prosigna® (Nanostring technologies, Seattle, WA) and Endopredict® (Myriad Genetics) are gene expression profiles that are used to predict the benefit of adjuvant chemotherapy and provide additional prognostic and/or predictive information. In this review, we discuss the role of gene expression signatures in treatment decision of patients with breast cancer.
Anahtar Kelime:

Erken Evre Meme Kanseri Tedavisinde Gen İmzalarının Rolü

Öz:
Meme kanseri çeşitli morfolojik, klinik ve moleküler özelliklere sahip heterojen bir hastalıktır. Adjuvan tedavi endikasyonunu belirlemek için geleneksel olarak patolojik parametreler ve hastalığın klinik evresi kullanılır, ancak bu özellikler tedaviye ihtiyacı olan hastaları belirlemek için yeterli değildir. Kişiselleştirilmiş tedaviler geliştirmek için prognostik ve prediktif biyobelirteçlere ihtiyaç vardır. Prediktif faktörler, belirli bir tedaviye yanıtın göstergeleridir. MammaPrint® (Agendia, Amsterdam, Hollanda), Oncotype DX® (Genomic Health, Redwood City, CA), Prosigna® (Nanostring teknolojileri, Seattle, WA) ve Endopredict® (Myriad Genetics) adjuvan kemoterapinin yararı ve ek prognostik ve/veya prediktif bilgileri tahmin etmek için kullanılan gen ekspresyon profilleridir. Bu derlemede, meme kanserli hastaların tedavi kararında gen ekspresyon imzalarının rolünü güncel literatür ışığında tartışmayı hedefledik.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1 Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009; 6 (4).
  • 2 Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart MJ, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; (8):1533–46.
  • 3 Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001; 19(4): 980–91.
  • 4 Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005; 23(12): 2716– 25.
  • 5 Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, et al. PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012; 107(5): 800–7.
  • 6 Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010; 7(12): 725–32.
  • 7 Eberlein TJ. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. Yearb Surg. 2006; 2006: 317–9.
  • 8 Sotiriou C, Pusztai L. Gene-Expression Signatures in Breast Cancer. N Engl J Med. 2009; 360(8): 790–800.
  • 9 Azim JA, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, et al. Utility of prognostic genomic tests in breast cancer practice: The impakt 2012 working group consensus statement. Ann Oncol. 2013; 24(3): 647–54.
  • 10 Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Blair SL, et al. NCCN Guidelines Version 5.2021 Breast Cancer NCCN Guidelines Panel Disclosures Su. 2021.
  • 11 Sparano JA, Paik S. Development of the 21- gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008; 26(5): 721–8.
  • 12 Paik S. Development and Clinical Utility of a 21‐Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen. Oncologist. 2007; 12(6): 631–5.
  • 13 Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer. J Natl Cancer Inst. 1997; 89(22): 1673–82.
  • 14 Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffinembedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005; 23(29): 7265–77.
  • 15 Murillo SM, Gasol Cudós A, Rodriguez A, Canosa Morales C, Olivé JM, Vilardell F, et al. 21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive/HER2-negative earlystage breast cancer. J Clin Oncol. 2020; 38(15_suppl): e12630–e12630.
  • 16 Sella T, Gelber SI, Poorvu PD, Kim HJ, Guzman Arocho YD, Collins LC, et al. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. J Clin Oncol. 2020; 38(15_suppl): 514–514.
  • 17 Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018; 379(2): 111–21.
  • 18 Stemmer SM, Steiner M, Rizel S, Soussan- Gutman L, Ben-Baruch N, Bareket-Samish A, et al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. npj Breast Cancer. 2017; 3(1): 33.
  • 19 Albanell J, Svedman C, Gligorov J, Holt SDH, Bertelli G, Blohmer JU, et al. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2– negative early-stage breast ca. Eur J Cancer. 2016; 66: 104–13.
  • 20 Network. NCC. NCCN Clinical Practice Guidelines in Oncology; Breast Cancer Version 3.2021. wwwNCCN.org. 2021
  • 21 Albain K, Barlow W, Shak S, Horobagyi G, Livingston R, Yeh I-T, et al. Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor- Positive Breast Cancer. Lancet Oncol. 2010; 11(1): 55– 65.
  • 22 Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol. 2010; 28(11): 1829–34.
  • 23 Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: First prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016; 34(20): 2341–9.
  • 24 Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: A SEER population-based study. npj Breast Cancer. 2016;2(1).
  • 25 Jasem J, Fisher CM, Amini A, Shagisultanova E, Rabinovitch R, Borges VF, et al. The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER trial on chemotherapy decision-making: Have clinicians already decided? JNCCN J Natl Compr Cancer Netw. 2017; 15(4): 494–503.
  • 26 Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8): 717–29.
  • 27 Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011; 17(18): 6012–20.
  • 28 Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br J Cancer. 2013; 109(12): 2959–64.
  • 29 Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018; 4(4): 545–53.
  • 30 Müller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, Prinzler J, et al. The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLoS One. 2013;8(6).
  • 31 Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014; 25(2): 339–45.
  • 32 Lænkholm AV, Jensen MB, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018; 36(8): 735–40.
  • 33 Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22): 2783– 90.
  • 34 Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004; 5(6): 607–16.
  • 35 Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Kranenbarg EMK, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HRþ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021; 27(1): 311–9.
  • 36 Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013; 105(14): 1036–42.
  • 37 Blok EJ, Kroep JR, Kranenbarg EMK, Duijm-De Carpentier M, Putter H, Van Den Bosch J, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 2018; 110(1): 40–8.
  • 38 Bartlett JMS, Sgroi DC, Treuner K, Zhang Y, Ahmed I, Piper T, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial. Ann Oncol. 2019; 30(11): 1776–83.
APA SONMEZ O, SENOCAK TASCI E (2021). The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. , 256 - 263. 10.5505/aot.2021.46693
Chicago SONMEZ OZLEM,SENOCAK TASCI ELİF The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. (2021): 256 - 263. 10.5505/aot.2021.46693
MLA SONMEZ OZLEM,SENOCAK TASCI ELİF The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. , 2021, ss.256 - 263. 10.5505/aot.2021.46693
AMA SONMEZ O,SENOCAK TASCI E The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. . 2021; 256 - 263. 10.5505/aot.2021.46693
Vancouver SONMEZ O,SENOCAK TASCI E The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. . 2021; 256 - 263. 10.5505/aot.2021.46693
IEEE SONMEZ O,SENOCAK TASCI E "The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer." , ss.256 - 263, 2021. 10.5505/aot.2021.46693
ISNAD SONMEZ, OZLEM - SENOCAK TASCI, ELİF. "The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer". (2021), 256-263. https://doi.org/10.5505/aot.2021.46693
APA SONMEZ O, SENOCAK TASCI E (2021). The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. ACTA ONCOLOGICA TURCICA, 54(2), 256 - 263. 10.5505/aot.2021.46693
Chicago SONMEZ OZLEM,SENOCAK TASCI ELİF The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. ACTA ONCOLOGICA TURCICA 54, no.2 (2021): 256 - 263. 10.5505/aot.2021.46693
MLA SONMEZ OZLEM,SENOCAK TASCI ELİF The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. ACTA ONCOLOGICA TURCICA, vol.54, no.2, 2021, ss.256 - 263. 10.5505/aot.2021.46693
AMA SONMEZ O,SENOCAK TASCI E The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. ACTA ONCOLOGICA TURCICA. 2021; 54(2): 256 - 263. 10.5505/aot.2021.46693
Vancouver SONMEZ O,SENOCAK TASCI E The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer. ACTA ONCOLOGICA TURCICA. 2021; 54(2): 256 - 263. 10.5505/aot.2021.46693
IEEE SONMEZ O,SENOCAK TASCI E "The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer." ACTA ONCOLOGICA TURCICA, 54, ss.256 - 263, 2021. 10.5505/aot.2021.46693
ISNAD SONMEZ, OZLEM - SENOCAK TASCI, ELİF. "The Role of Gene Signatures on Treatment Decisions in Early-Stage Breast Cancer". ACTA ONCOLOGICA TURCICA 54/2 (2021), 256-263. https://doi.org/10.5505/aot.2021.46693
Sayfa Oluşturulma Tarihi
23-04-2024 20:44

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları